Topix
Advanced Cell Technology, Inc. , a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in the company's Phase I/II clinical trial for dry age-related macular degeneration using retinal pigment epithelial cells derived from human embryonic stem cells .